Melgarejo-Segura, M.T.; Zambudio-Munuera, A.; Arrabal-Polo, M.Á.; Lardelli-Claret, P.; Pareja-Vilchez, M.; Arrabal-Martín, M.
Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive Bladder Cancer. Cancers 2025, 17, 453.
https://doi.org/10.3390/cancers17030453
AMA Style
Melgarejo-Segura MT, Zambudio-Munuera A, Arrabal-Polo MÁ, Lardelli-Claret P, Pareja-Vilchez M, Arrabal-Martín M.
Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive Bladder Cancer. Cancers. 2025; 17(3):453.
https://doi.org/10.3390/cancers17030453
Chicago/Turabian Style
Melgarejo-Segura, Maria Teresa, Alberto Zambudio-Munuera, Miguel Ángel Arrabal-Polo, Pablo Lardelli-Claret, Manuel Pareja-Vilchez, and Miguel Arrabal-Martín.
2025. "Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive Bladder Cancer" Cancers 17, no. 3: 453.
https://doi.org/10.3390/cancers17030453
APA Style
Melgarejo-Segura, M. T., Zambudio-Munuera, A., Arrabal-Polo, M. Á., Lardelli-Claret, P., Pareja-Vilchez, M., & Arrabal-Martín, M.
(2025). Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive Bladder Cancer. Cancers, 17(3), 453.
https://doi.org/10.3390/cancers17030453
